HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weinstein, M C Articles by Goldman, L Search for Related Content PubMed PubMed Citation Articles by Weinstein, M C Articles by Goldman, L

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.

M C Weinstein, P G Coxson, L W Williams, T M Pass, W B Stason and L Goldman

Institute for Health Research, Harvard School of Public Health, Boston, MA 02115.

A computer simulation model was developed to project the future mortality, morbidity, and cost of coronary heart disease (CHD) in the United States population. The model contains a demographic-epidemiologic (DE) submodel, which stimulates the distribution of coronary risk factors and the conditional incidence of CHD in a demographically evolving population; a "bridge" submodel, which determines the outcome of the initial CHD event; and a disease history (DH) submodel, which simulates subsequent events in persons with a previous CHD event. The user of the model may simulate the effects of interventions, either preventive (i.e., risk factor modification) or therapeutic, upon mortality, morbidity, and cost for up to a 30-year period. If there were no future changes in risk factors or the efficacy of therapies after 1980, baseline projections indicate that the aging of the population, and especially the maturation of the post-World War II baby-boom generation, would increase CHD prevalence and annual incidence, mortality, and costs by about 40-50 per cent by the year 2010. Unprecedented reductions in risk factors would be required to offset these demographic effects on the absolute incidence of CHD. The specific forecasts could be inaccurate, however, as a consequence of erroneous assumptions or misestimated baseline data, and the model awaits validation based on actual future data.

This article has been cited by other articles:

				K. Bibbins-Domingo, P. Coxson, M. J. Pletcher, J. Lightwood, and L. Goldman Adolescent Overweight and Future Adult Coronary Heart Disease N. Engl. J. Med., December 6, 2007; 357(23): 2371 - 2379. [Abstract] [Full Text] [PDF]

				J. Karnon, A. Brennan, and R. Akehurst A Critique and Impact Analysis of Decision Modeling Assumptions Med Decis Making, August 1, 2007; 27(4): 491 - 499. [Abstract] [PDF]

				W. E. Pelham, E. M. Foster, and J. A. Robb The Economic Impact of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents J. Pediatr. Psychol., July 1, 2007; 32(6): 711 - 727. [Abstract] [Full Text] [PDF]

				E. Huovinen, T. Harkanen, T. Martelin, S. Koskinen, and A. Aromaa Predicting coronary heart disease mortality--assessing uncertainties in population forecasts and death probabilities by using Bayesian inference Int. J. Epidemiol., October 1, 2006; 35(5): 1246 - 1252. [Abstract] [Full Text] [PDF]

				S. M. Shechter, A. J. Schaefer, R. S. Braithwaite, and M. S. Roberts Increasing the efficiency of monte carlo cohort simulations with variance reduction techniques. Med Decis Making, September 1, 2006; 26(5): 550 - 553. [Abstract] [PDF]

				E. J. Dasbach, E. H. Elbasha, and R. P. Insinga Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and Disease Epidemiol. Rev., August 1, 2006; 28(1): 88 - 100. [Abstract] [Full Text] [PDF]

				A Walker, J McMurray, S Stewart, W Berger, A D McMahon, H Dargie, K Fox, S Hillis, N J K Henderson, and I Ford Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart, May 1, 2006; 92(5): 619 - 624. [Abstract] [Full Text] [PDF]

				R. L. Nijhuis, T. Stijnen, A. Peeters, J. C.M. Witteman, A. Hofman, and M. G. M. Hunink Apparent and Internal Validity of a Monte Carlo-Markov Model for Cardiovascular Disease in a Cohort Follow-up Study. Med Decis Making, March 1, 2006; 26(2): 134 - 144. [Abstract] [PDF]

				O. Alagoz, C. L. Bryce, S. Shechter, A. Schaefer, C.-C. H. Chang, D. C. Angus, and M. S. Roberts Incorporating Biological Natural History in Simulation Models: Empirical Estimates of the Progression of End-Stage Liver Disease Med Decis Making, November 1, 2005; 25(6): 620 - 632. [Abstract] [PDF]

				J. E. Smith and R. L. Keeney Your Money or Your Life: A Prescriptive Model for Health, Safety, and Consumption Decisions Management Science, September 1, 2005; 51(9): 1309 - 1325. [Abstract] [PDF]

				J. Critchley, J. Liu, D. Zhao, W. Wei, and S. Capewell Explaining the Increase in Coronary Heart Disease Mortality in Beijing Between 1984 and 1999 Circulation, September 7, 2004; 110(10): 1236 - 1244. [Abstract] [Full Text] [PDF]

				H. D. Sesso, R. S. Chen, G. J. L'Italien, P. Lapuerta, W. C. Lee, and R. J. Glynn Blood Pressure Lowering and Life Expectancy Based on a Markov Model of Cardiovascular Events Hypertension, November 1, 2003; 42(5): 885 - 890. [Abstract] [Full Text] [PDF]

				S.D. Ramsey and S.D. Sullivan The burden of illness and economic evaluation for COPD Eur. Respir. J., June 1, 2003; 21(41_suppl): 29S - 35s. [Abstract] [Full Text] [PDF]

				G Parmigiani Measuring uncertainty in complex decision analysis models Statistical Methods in Medical Research, December 1, 2002; 11(6): 513 - 537. [Abstract] [PDF]

				J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Empirically Calibrated Model of Hepatitis C Virus Infection in the United States Am. J. Epidemiol., October 15, 2002; 156(8): 761 - 773. [Abstract] [Full Text] [PDF]

				J.-M. Gaspoz, P. G. Coxson, P. A. Goldman, L. W. Williams, K. M. Kuntz, M.G. M. Hunink, and L. Goldman Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease N. Engl. J. Med., June 6, 2002; 346(23): 1800 - 1806. [Abstract] [Full Text] [PDF]

				D. H. Taylor Jr, V. Hasselblad, S. J. Henley, M. J. Thun, and F. A. Sloan Benefits of Smoking Cessation for Longevity Am J Public Health, June 1, 2002; 92(6): 990 - 996. [Abstract] [Full Text] [PDF]

				The CDC Diabetes Cost-effectiveness Group Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes JAMA, May 15, 2002; 287(19): 2542 - 2551. [Abstract] [Full Text] [PDF]

				J.A. Critchley and S. Capewell Why model coronary heart disease? Eur. Heart J., January 2, 2002; 23(2): 110 - 116. [Full Text] [PDF]

				D. J. Cohen, D. A. Taira, R. Berezin, D. A. Cox, M.-C. Morice, G. W. Stone, and C. L. Grines Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial Circulation, December 18, 2001; 104(25): 3039 - 3045. [Abstract] [Full Text] [PDF]

				L. Goldman, K. A. Phillips, P. Coxson, P. A. Goldman, L. Williams, M. G. M. Hunink, and M. C. Weinstein The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1012 - 1017. [Abstract] [Full Text] [PDF]

				M. L. Daviglus and J. Stamler Major risk factors and coronary heart disease: much has been achieved but crucial challenges remain J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1018 - 1022. [Full Text] [PDF]

				L. J. Shaw, A. E. Iskandrian, R. Hachamovitch, G. Germano, H. C. Lewin, T. M. Bateman, and D. S. Berman Evidence-Based Risk Assessment in Noninvasive Imaging J. Nucl. Med., September 1, 2001; 42(9): 1424 - 1436. [Abstract] [Full Text] [PDF]

				J. A. Tice, E. Ross, P. G. Coxson, I. Rosenberg, M. C. Weinstein, M. G. M. Hunink, P. A. Goldman, L. Williams, and L. Goldman Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocysteine Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond JAMA, August 22, 2001; 286(8): 936 - 943. [Abstract] [Full Text] [PDF]

				K. A. Phillips, M. G. Shlipak, P. Coxson, P. A. Heidenreich, M. G. M. Hunink, P. A. Goldman, L. W. Williams, M. C. Weinstein, and L. Goldman Health and Economic Benefits of Increased {beta}-Blocker Use Following Myocardial Infarction JAMA, December 6, 2000; 284(21): 2748 - 2754. [Abstract] [Full Text] [PDF]

				L. A. Prosser, A. A. Stinnett, P. A. Goldman, L. W. Williams, M. G.M. Hunink, L. Goldman, and M. C. Weinstein Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics Ann Intern Med, May 16, 2000; 132(10): 769 - 779. [Abstract] [Full Text] [PDF]

				S. H. Woolf The Need for Perspective in Evidence-Based Medicine JAMA, December 22, 1999; 282(24): 2358 - 2365. [Abstract] [Full Text] [PDF]

				K. M. Kuntz, J. Tsevat, M. C. Weinstein, and L. Goldman Expert Panel vs Decision-Analysis Recommendations for Postdischarge Coronary Angiography After Myocardial Infarction JAMA, December 15, 1999; 282(23): 2246 - 2251. [Abstract] [Full Text] [PDF]

				L. Goldman, P. Coxson, M. G. M. Hunink, P. A. Goldman, A. N. A. Tosteson, M. Mittleman, L. Williams, and M. C. Weinstein The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines J. Am. Coll. Cardiol., September 1, 1999; 34(3): 768 - 776. [Abstract] [Full Text] [PDF]

				A. L Hersh, W. C Black, and A. N. Tosteson Estimating the population impact of an intervention: a decision-analytic approach Statistical Methods in Medical Research, August 1, 1999; 8(4): 311 - 330. [Abstract] [PDF]

				A. D. Paltiel, J. A. Scharfstein, G. R. Seage, E. Losina, S. J. Goldie, M. C. Weinstein, D. E. Craven, and K. A. Freedberg A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection Med Decis Making, April 1, 1998; 18(2): S93 - S105. [Abstract] [PDF]

				A. N.A. Tosteson, M. C. Weinstein, M. G.M. Hunink, M. A. Mittleman, L. W. Williams, P. A. Goldman, and L. Goldman Cost-Effectiveness of Populationwide Educational Approaches to Reduce Serum Cholesterol Levels Circulation, January 7, 1997; 95(1): 24 - 30. [Abstract] [Full Text]

				D. C. H. Cheng, J. Karski, C. Peniston, B. Asokumar, G. Raveendran, J. Carroll, H. Nierenberg, S. Roger, D. Mickle, J. Tong, et al. MORBIDITY OUTCOME IN EARLY VERSUS CONVENTIONAL TRACHEAL EXTUBATION AFTER CORONARY ARTERY BYPASS GRAFTING: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL J. Thorac. Cardiovasc. Surg., September 1, 1996; 112(3): 755 - 764. [Abstract] [Full Text]

				E. L. Eisenstein, D. B. Mark, and R. M. Califf Importance of Cost and Quality of Life in Decisions About Routine Angiography After Acute Myocardial Infarction: The Role of Cost-effectiveness Models Circulation, September 1, 1996; 94(5): 869 - 871. [Full Text]

				K. M. Kuntz, J. Tsevat, L. Goldman, and M. C. Weinstein Cost-effectiveness of Routine Coronary Angiography After Acute Myocardial Infarction Circulation, September 1, 1996; 94(5): 957 - 965. [Abstract] [Full Text]

				M. Johannesson, J. S. Pliskin, and M. C. Weinstein Are Healthy-years Equivalents an Improvement over Quality-adjusted Life Years? Med Decis Making, December 1, 1993; 13(4): 281 - 286. [Abstract] [PDF]

				R. W. Klein, R. S. Dittus, S. D. Roberts, and J. R. Wilson Simulation Modeling and Health-care Decision Making Med Decis Making, December 1, 1993; 13(4): 347 - 354. [PDF]